Table 2 MEST-C score distribution in STOP-IgAN patients
From: Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)
All (SUP + IMM) | Supportive Care (SUP) | Supportive Care plus Immunosuppression (IMM) | |
|---|---|---|---|
(N = 70) | (N = 32) | (N = 38) | |
Mesangial hypercellularity | |||
M0 | 52 (74%) | 24 (75%) | 28 (74%) |
M1 | 18 (26%) | 8 (25%) | 10 (26%) |
Endocapillary hypercellularity | |||
E0 | 58 (83%) | 27 (84%) | 31 (82%) |
E1 | 12 (17%) | 5 (16%) | 7 (18%) |
Segmental glomeruloscerlosis | |||
S0 | 6 (9%) | 3 (9%) | 3 (8%) |
S1 | 64 (91%) | 29 (91%) | 35 (92%) |
Tubular atrophy/Interstitial fibrosis | |||
T0 | 41 (59%) | 15 (47%) | 26 (68%) |
T1 | 26 (37%) | 17 (53%) | 9 (24%) |
T2 | 3 (4%) | 0 (0%) | 3 (8%) |
Crescents | |||
C0 | 48 (69%) | 24 (75%) | 24 (63%) |
C1 | 17 (24%) | 7 (22%) | 10 (26%) |
C2 | 5 (7%) | 1 (3%) | 4 (11%) |